Skip to main content
SpringerLink
Log in

Neue Behandlungsansätze in Studien

Therapie des nicht resektablen, metastasierten Melanoms

  • Fortbildung
  • Therapie des nicht resektablen, metastasierten Melanoms
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Noch immer verstirbt ein Großteil der Patienten mit nicht resektablemmetastasiertem Melanom aufgrund von Therapieresistenzen.

© Clinical Photography / Science Photo Library

Abb. 1

Literatur

  1. Nathan P et al. Five-year analysis of dabrafenib plus trametinib in patients with BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol. 2019; 37: 9507

  2. Gogas HJ et al. Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. J Clin Oncol. 2020; 38 (suppl): 10012

  3. Larkin J et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of Nivolumab plus Ipilimumab (Nivo+Ipi) combination therapy in advanced melanoma. Ann Oncol. 2019; 30 (suppl): 851-934

  4. Long G et al. Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma. J Clin Oncol. 2020; 38 (suppl): 10013

  5. Tawbi HAH et al. Efficacy and safety of the combination of Nivolumab (Nivo) plus Ipilimumab (Ipi) in patients with symptomatic melanoma brain metastases (CheckMate 204). J Clin Oncol. 2019; 37 (suppl): 9501

  6. Long G et al. Long-term outcomes from the randomized phase II study of Nivolumab (Nivo) or Nivo+Ipilimumab (Ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC). J Clin Oncol. 2019; 37 (suppl): 3661

  7. Long G et al. The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. J Clin Oncol. 2020; 38 (suppl): 10028

  8. Nathan P et al. Spartalizumab plus dabrafenib and trametinib (Sparta- DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. Ann Oncol. 2020; 31 (4): 1142-215

  9. Gutzmer R et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395: 1835-44

  10. Arance AM et al. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (WT) advanced melanoma: Primary analysis from the phase 3 IMSPIRE170 trial. Ann Oncol. 2019; 30 (suppl): 906

  11. Shoushtari A, et al. Long-term outcomes in patients with mucosal melanoma. J Clin Oncol. 2020; 38 (suppl): 10019

  12. Heppt MV et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019; 7: 299

  13. Middleton M, et al. Pharmacodynamic effect of IMCgp100 (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma. J Clin Oncol. 2019; 37 (suppl): 9523

  14. Hamid O et al. Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma. J Clin Oncol. 2019; 37 (suppl): 9530

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistr. 52 (W14), 20246, Hamburg, Germany

    Christoffer Gebhardt

Authors
  1. Christoffer Gebhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoffer Gebhardt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gebhardt, C. Therapie des nicht resektablen, metastasierten Melanoms. hautnah dermatologie 37, 26–31 (2021). https://doi.org/10.1007/s15012-021-6600-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-021-6600-5

Search

Navigation